This study was an observational, retrospective, single centre study; it was approved by our local Institutional Review Board (IRB), which waived the need for informed consent, and conducted in accordance with institutional guidelines, including the Declaration of Helsinki (Ethics Committee code: 784/2021/Oss/AOUBo).
One hundred forty patients with at least one PI-RADS 3 lesion, according to the ESUR guidelines version 2.1 at mpMRI performed at our Radiology Unit from September 2019 to December 2021 were enrolled.
The inclusion criteria were the following: 1) having undergone fusion-TB of the index lesion at our Radiology Unit and 2) having a histopathological report from a dedicated pathologist of the Pathology Unit of our institution.
The exclusion criteria were the following: 1) no concomitant PI-RADS 4 or 5 lesions; 2) mpMRI protocol not completely adhering to the suggested imaging protocols described in PI-RADS version 2.1; 3) active surveillance and previous surgical treatment, such as open simple prostatectomy (OP) or transurethral resection of the prostate (TURP); 4) the presence of severe artifacts, not allowing the evaluation of one or more sequences of the mpMRI due to uni/bilateral hip prostheses or other causes.
After application of the exclusion criteria, 120 patients were included in the final analysis (Figure 1
For each patient enrolled, clinical data, such as PSA, prostate volume, and PSA density, were collected.
One hundred forty patients with at least one PI-RADS 3 lesion, according to the ESUR guidelines version 2.1 at mpMRI performed at our Radiology Unit from September 2019 to December 2021 were enrolled.
The inclusion criteria were the following: 1) having undergone fusion-TB of the index lesion at our Radiology Unit and 2) having a histopathological report from a dedicated pathologist of the Pathology Unit of our institution.
The exclusion criteria were the following: 1) no concomitant PI-RADS 4 or 5 lesions; 2) mpMRI protocol not completely adhering to the suggested imaging protocols described in PI-RADS version 2.1; 3) active surveillance and previous surgical treatment, such as open simple prostatectomy (OP) or transurethral resection of the prostate (TURP); 4) the presence of severe artifacts, not allowing the evaluation of one or more sequences of the mpMRI due to uni/bilateral hip prostheses or other causes.
After application of the exclusion criteria, 120 patients were included in the final analysis (
For each patient enrolled, clinical data, such as PSA, prostate volume, and PSA density, were collected.
Free full text: Click here
